Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

PURPOSE: The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We also s...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Shulman, Lawrence N., Cirrincione, Constance T., Berry, Donald A., Becker, Heather P., Perez, Edith A., O'Regan, Ruth, Martino, Silvana, Atkins, James N., Mayer, Erica, Schneider, Charles J., Kimmick, Gretchen, Norton, Larry, Muss, Hyman, Winer, Eric P., Hudis, Clifford
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2012
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494835/
https://ncbi.nlm.nih.gov/pubmed/22826271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.6405
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak